

# Wei-Yun Lai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1684248/publications.pdf>

Version: 2024-02-01

15  
papers

805  
citations

758635

12  
h-index

996533

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1355  
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of <i>ALK</i> mutation. <i>EMBO Journal</i> , 2021, 40, e105784.	3.5	35
2	PINK1-Mediated Inhibition of EGFR Dimerization and Activation Impedes EGFR-Driven Lung Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 1745-1757.	0.4	1
3	11q Deletion or ALK Activity Curbs DLC2 Expression to Maintain an Undifferentiated State in Neuroblastoma. <i>Cell Reports</i> , 2020, 32, 108171.	2.9	25
4	P2.03b-090 A CTLA-4 Antagonizing DNA Aptamer with Anti-Tumor Effect. <i>Journal of Thoracic Oncology</i> , 2017, 12, S991.	0.5	0
5	A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 520-528.	2.3	46
6	Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1 $\alpha$ /HDAC1/Slug axis. <i>Nature Communications</i> , 2016, 7, 13867.	5.8	69
7	A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e397.	2.3	114
8	Fluorescence-Guided Probes of Aptamer-Targeted Gold Nanoparticles with Computed Tomography Imaging Accesses for in Vivo Tumor Resection. <i>Scientific Reports</i> , 2015, 5, 15675.	1.6	73
9	Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e150.	2.3	7
10	Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. <i>Biomaterials</i> , 2014, 35, 2905-2914.	5.7	57
11	CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis. <i>Neoplasia</i> , 2014, 16, 441-450.	2.3	23
12	A nanoscale drug-entrapment strategy for hydrogel-based systems for the delivery of poorly soluble drugs. <i>Biomaterials</i> , 2009, 30, 2102-2111.	5.7	76
13	The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents. <i>Biomaterials</i> , 2009, 30, 79-88.	5.7	73
14	Mechanical properties, drug eluting characteristics and in vivo performance of a genipin-crosslinked chitosan polymeric stent. <i>Biomaterials</i> , 2009, 30, 5560-5571.	5.7	59
15	Rapidly Self-Expandable Polymeric Stents with a Shape-Memory Property. <i>Biomacromolecules</i> , 2007, 8, 2774-2780.	2.6	142